Authors
Latest:
Dr. Barzi on the Need for More Sensitive MRD Testing in CRCAfsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.
Latest:
Expert Teams, Exceptional Outcomes: AHN Cancer Institute’s Disease Site Centers Drive InnovationAHN Cancer Institute’s Centers of Excellence unite teams of experts to provide patients with high-quality, collaborative care in a supportive environment.
Latest:
Fellows on Film: How To Market Yourself for a FellowshipRichard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.
Latest:
Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCLBrian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.
Latest:
Choosing Your PathMegan M. Dupuis, MD, shares the complex journey she traveled during medical training and how it brought her to the academic setting.
Latest:
Dr Hillengass on the Rationale For Investigating the Effect of Exercise on Functional Performance in Multiple MyelomaJens Hillengass, MD, PhD, discusses the rationale for investigating exercise and its effect on functional performance in multiple myeloma, and highlights the methods utilized in this study.
Latest:
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MDDr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.
Latest:
Targeting Transcription as a New Frontier in Advanced Pancreatic CancerA new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.
Latest:
Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial CancerElias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.
Latest:
Dr Baljevic on the PERSEUS Trial in Untreated Multiple MyelomaMuhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.
Latest:
Dr Halperin on the FDA Approval of Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETsDaniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.
Latest:
Oncology Fellows Derive the Greatest Benefit From Advanced Research TrainingAimed at growing the translational workforce, most hubs offer different accelerated advanced degree opportunities to oncology trainees, such as master’s degrees in clinical and/or translational research, or graduate certificates.
Latest:
A Gut Check on the Digital Divide: How Wearable Devices Are Changing Cancer CareThe idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.
Latest:
Dr. Lang on the Potential Applications for the Parsortix® PC1 System in Breast CancerJulie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.
Latest:
Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 TrialMisako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.
Latest:
Risk of Lymphedema Is Comparable With Hypofractionated Radiation in Early Breast CancerThe risk of lymphedema was comparable for hypofractionated radiation therapy and normofractionated radiation therapy in early breast cancer.
Latest:
Dr. Mohyuddin on Improving Survival in Multiple MyelomaGhulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.
Latest:
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell LymphomaJason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.
Latest:
Dr. del Rio on Remaining Questions With the COVID-19 VaccinesCarlos del Rio, MD, discusses remaining questions with the COVID-19 vaccines.
Latest:
Dr. Gonzalez-Junca on Combining IL-21 and IL-15 in NK-Cell TherapyAlba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.
Latest:
KRAS G12C Inhibitors in mCRCA brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.
Latest:
Dr. Nguyen on Enrollment Disparities in Pivotal Clinical Trials in OncologyRyan Nguyen, DO, discusses enrollment disparities in pivotal clinical trials in oncology.
Latest:
Dr. Majhail on the Importance of Utilizing Social Media in OncologyNavneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.
Latest:
Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast CancerHeather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.
Latest:
Dr. Figel on Preclinical Research With Survivin Isoforms in Cancer CellsSheila Figel, PhD, a neuro-oncologic scientist with Roswell Park Comprehensive Cancer Center, discusses preclinical research with canonical and noncanonical that are displayed on the surface of cancer cells.
Latest:
Novel HER2-Targeted Therapies for NSCLCClosing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
Latest:
Getting the Best From MentorshipMentors may help in career development, personal matters, research activities, and professional growth.
Latest:
Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR MutationsAaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.
